The goal of this investigator-initiated, single-center, and randomized phase II trial is to
investigate the potential synergistic effect of combining stereotactic body radiotherapy of a
single soft tissue- or bone metastasis with ipilimumab and nivolumab in patients with mCRPC
and perform translational analyses on tissue and blood, searching for predictive biomarkers
of efficacy and toxicity.
Participants will be randomized to receive ipilimumab and nivolumab with or without
stereotactic body radiotherapy (SBRT).